Groningen Antithrombin Study
Completed
- Conditions
- venous thrombosis and pulmonary embolism1000533010014523
- Registration Number
- NL-OMON39175
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 250
Inclusion Criteria
Patient who presented with VTE in our hospital, and were also diagnosed with inherited antithrombin deficieny. (Definition: antithrombin deficiency, measured twice, and also found in at least one family member)
Their family members
Age >= 18 years
Written informed consent
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1. Number of VTE*s, riskfactors for VTE, treatment for VTE<br /><br>2. Antithrombin antigen and activity levels<br /><br>3. Genetic mutations in the SERPINC1 gene</p><br>
- Secondary Outcome Measures
Name Time Method <p>• To calculate the absolute and relative risk of VTE in patients with<br /><br>antithrombine deficiency, compared with non-deficient family members (update<br /><br>on previous study)<br /><br>• To describe current anti-coagulant therapy and history of effectiveness and<br /><br>safety of anti-coagulant therapy</p><br>